

HLX43 First-in-human Study Data Readout

Presenter

Date

Sponsor

First Clinical-stage, Biomarker-independent ADC with IO Activity

Broad Therapeutic Effects

IO&chemo treated




Potential of HLX43



Future Plans

Background

Molecular components of HLX43




Key Features



TME-activatable
tripeptide linker

HLX43-FIH101 Study Design


cutoff date 2025/06/28



Efficacy in NSCLC patients per RECIST v1.1.



Tumor response in NSCLC patients per RECIST v1.1.





Tumor response	ORR % (95% CI)	DCR % (95% CI)
----------------	----------------	----------------


--	--

--	--


NSCLC,

Subgroup analysis of tumor response per RECIST v1.1.






Immune-related adverse events



Best % change from baseline in target lesion size



HLX43 is capable of eliciting immunotherapeutic effects

Conclusions

Outstanding efficacy in NSCLC

- ✓ IO- and chemo-treated Squamous NSCLC (≥ 4L) ✓
 - ✓
 - ✓
 - ✓
- ! " ")21
- EGFR
- (" %
- Y (

Biomarker independent:

Favorable safety profile with low hematologic toxicities

HLX07HLX10-sqNSCLC201 Study

Data Readout

Presenter


Date

Sponsor


Background

Previous analysis presented at the 2025 ASCO Annual Meeting showed encouraging efficacy of the tri-combination regimen. Here we report an updated analysis of the efficacy and safety findings.

Study design




Patient disposition




Primary endpoint: BICR-assessed ORR per RECIST v1.1

Endpoint (according to BICR assessments)	Group A (n = 13)	Group B (n = 14)
	69.2	71.4
	92.3	100.0

Duration of response as assessed by BICR per RECIST v1.1



Primary endpoint: BICR-assessed PFS





Tri-combination therapy of HLX07, serplulimab and chemotherapy demonstrated encouraging efficacy along with manageable safety profile for patients with advanced sqNS 15363

!



Disclaimer





Reliable Quality

Reliable Quality
Affordable Innovation

